is dreaming of Nicosan4All ;-)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Switched on Cranfield scientists find sickle cell clue
Written by Lautaro Vargas
Thursday, 11 June 2009
Cranfield University scientists are being funded to research a cure for sickle cell disease, an inherited blood disorder that reduces blood flow to organs and can lead to strokes.
Funded by Action Medical Research, Dr Dave Carter and Dr Ryan Pink from Cranfield Health will start work next year on finding a new treatment for the debilitating sickle cell disease (SCD), which affects 12,500 suffers in the UK and around 20-25million worldwide.
Red blood cells in sufferers of SCD contain an abnormal type of haemoglobin, which sometimes become sickle – or crescent – shaped and so have difficulty passing through small blood vessels.
When these sickle-shaped cells block small blood vessels, less blood can reach that part of the body. Tissue that does not receive a normal blood flow eventually becomes damaged and causes the complications of SCD. It is the large blockages, however, which cause the most damage to organs, often resulting in complications such as strokes.
Current treatments work by reactivating the gamma-globin gene, which is normally switched off from birth. While effective, this indirectly results in cells in the body being killed off.
Dr Carter and Dr Pink believe that the gamma-globin gene can be switched back on without it affecting other genes or killing off cells. They will develop the technique on blood cells grown outside the body and, if successful, it may eventually be used to reduce the symptoms in SCD patients.
http://www.businessweekly.co.uk/2009061135072/academia-and-research/switched-on-cranfield-scientists-find-sickle-cell-clue.html
Thanks, had not noted the connection (Mof Health). Many of us have wondered out loud about the suit against the Gov of N. ... and where's the money coming from for this filing even? RS's personal account with an IOU from the X? lol. Wish I could be in the courtroom coming up, listening to Hasler and Swift ... when do the gloves come off?
UNITED STATES BANKRUPTCY COURT
- NORTHERN DISTRICT OF ILLINOIS -
THE HONORABLE JACK SCHMETTERER, PRESIDING
LOCATION: COURTROOM 682
EASTERN DIVISION
Thursday, June 18, 2009
Updated 06/09/2009 @ 06:38:PM CST
11:30 AM
09ap00358
This[9]
Orig[8] XECHEM INC 08BK30512, XECHEM INTERNATIONAL, INC. V. NATIONAL INSTITUTE FOR PHARMACEUTICAL RESEARCH AND AP
Notice of Motion and Motion to Dismiss Adversary Proceeding Filed by B Lane Hasler on behalf of Uford S. Inyang, National Institute for Pharmaceutical Research and Development, Babatunde Osotimehim.
09ap00358
This[10] XECHEM INC 08BK30512, XECHEM INTERNATIONAL, INC. V. NATIONAL INSTITUTE FOR PHARMACEUTICAL RESEARCH AND AP
Notice of Motion and Motion to Dismiss Adversary Proceeding Filed by B Lane Hasler on behalf of Uford S. Inyang, National Institute for Pharmaceutical Research and Development, Babatunde Osotimehim.
08bk30512
This[152]
Orig[146] XECHEM INC CH. 11
Notice of Motion and Motion to Compel Production Pursuant to March 20 Rule 2004 Order Filed by Robert E Richards on behalf of Official Committee of Unsecured Creditors of Xechem, Inc. et al..
08bk30513
This[93]
Orig[81] XECHEM INTERNATIONAL, INC. CH. 11
Incorrect PDF-Filer Notified to Refile Notice of Motion and Motion to Disallow Objection to Proof of Claim Number 37 filed by Renuka Misra Filed by Stephen A Metz on behalf of Renuka Misra Ph D.
08bk30513
This[98] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 37 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
http://www.ilnb.uscourts.gov/cci/0618A339.htm
Excellent Work Sir M
Agreed with Absolute Certainty eom
Bobby Engram was a great player for the Seattle Seahawks: very productive, a consummate professional, and a good presence in the locker room. He has recently moved on (to Kansas City), but his presence is still being felt in the Pacific Northwest.
In 2007, Bobby Engram started his own foundation with the purpose of helping find a cure for Sickle Cell Anemia – the same disease that afflicts his daughter. The Bobby Engram Foundation has been successful in raising awareness of the disease, and will continue the pursuit for a cure.
Next weekend, the Bobby Engram Foundation will be hosting its second annual celebrity softball game with the intention of raising funds and awareness. All proceeds from the event will benefit Sickle Cell Anemia research.
... more
http://12thmanrising.com/2009/06/05/bobbyengramfoundation/
The Bobby Engram Foundation
Mission Statement
The Bobby Engram Foundation strives to provide hope, courage and opportunity to underprivileged children who suffer from chronic pain that affects their lives physically or emotionally.
About Bobby
SIMON J. “BOBBY” ENGRAM III will begin his 14th season as an NFL wide receiver for a new team, the Kansas City Chiefs. Bobby Spent the last eight seasons with the Seattle Seahawks and leaves Seattle as the team’s all-time post season catch leader and as the franchise’s all time leader in single season catches. In 2004 he helped lead the team to an NFC Championship. Over his career, which began with the Bears in 1996, Bobby has amassed over 9,000 yards in offense, 650 catches and 37 touchdowns. Bobby played his collegiate football with Penn State University where his gaudy pile of records stood undisturbed for 13 years. Though the pile is slightly smaller as of this year, Bobby still holds the majority of Penn State’s receiving records including the all time yardage and touchdown marks. Bobby won the first ever Biletnikoff Award for the nation’s top collegiate wide receiver and participated in Penn State’s perfect season in 1994.
But what sets Bobby apart from other athletes has more to do about who he is as a man rather than who he is as a football player. Few underestimate a man who has managed to endure as a full contact slot ready receiver for nearly a decade and a half. He has been valued as a leader on every team he has played for. In addition, if you check his trophy case, you will find: The Ed Block Courage Award, The Seattle Seahawks Community Man of the Year, the Home Depot NFL Neighborhood MVP Award, The President’s Volunteer Award as well as commendation from both the Washington State House and Senate for his work to help those who suffer from Sickle Cell Disease. Bobby’s daughter, 11 year old Bobbi, has Sickle Cell Disease.
Bobby continues his work in the NFL while managing his Foundation, The Bobby Engram Foundation, which seeks to conquer the disease that affects his daughter. There is no doubt that Bobby will be remembered as the enduring leader who overcame adversity through a long and storied career as a professional athlete. But what matters most to him is that he be remembered as a man whose faith and ethic inspired those around him.
http://www.bobbyengramfoundation.org/home.html
LoChute has competition as you may have noted... we want an upgrade to HiChute...
(turn pics on)
there is no denying this ... and I had already updated my previous with a 2nd thot... ... is it hot and humid in Abuja?
Seems to me you will need to earn your stripes on this one... picking employment out of Xgem is all work with little pay (lol)
... on 2nd thought... me thinks u have already earned the full rainbow compliment of stripes... ... so we will pay you well... ~ S
That last sentence of yours is quite a revelation to me, and I am not referring to the known fact that he's provided no benefit to the company! Is that Dr. Pandeys postion as well?
Lots of bickering going on imo... in the courts I mean...
THE HONORABLE JACK SCHMETTERER, PRESIDING
LOCATION: COURTROOM 682
EASTERN DIVISION
http://www.ilnb.uscourts.gov/m/Judge/Schmetterer/Court_Calendar_Loader_m.cfm?file=0605A339_m.htm
Free testing for sickle cell trait at Schenley Park today
Saturday, May 30, 2009
Pittsburgh Post-Gazette
Individuals and families can receive free testing for the sickle cell trait during an educational event Children's Hospital of Pittsburgh of UPMC's Sickle Cell Program is holding today at Schenley Park in Oakland.
The event at the Vietnam Veterans Pavilion will run from noon to 6 p.m. with registration beginning at 11 a.m. and will include testing throughout the day. There also will be informational sessions, panel discussions, free food, and entertainment including performances by area choirs, mimes and soloists.
Sickle cell disease, also called sickle cell anemia, is an inherited blood disorder that affects approximately 80,000 people in the United States, the majority of them African-American. Sickle cell can cause extreme pain, strokes, damage to organs including the heart, kidneys and lungs, and a shortened life expectancy. It is characterized by defective hemoglobin, a protein in red blood cells that carries oxygen to the body.
Testing for the sickle cell trait is crucial so carriers will know their risk of passing on the disease. Children are born with the blood disorder only if two sickle cell genes are inherited, one from each parent. A person who has only one sickle cell gene is healthy but is considered a carrier of the disease.
First published on May 30, 2009 at 12:00 am
Looking forward to press like this for Nicosan/Hemoxin/Zickle or whatever it will be called on this continent... Happy Anniversary LoChute - a good celebration.
http://www.post-gazette.com/pg/09150/973835-53.stm
H.0007 L.0004 C.0005 V45M imo
It will be six to twelve months before new production may be available in a best-case scenario imo... do you think (hope) there might be some of the good stuff left in a back room at XPNL as potential interim supply?
AMA, I like to think that Dr. Swift is 'up' on the developments in 'his' field, but who really knows... after all is said and done, XKEM does not have the drug ... today.
ps... thanx LOCHUTE
Sickle Cell and Thalassemia patients can’t get proper treatment in Ontario
By John Bonnar | May 26, 2009
The Coalition to Save Our Young Adults called on the Ontario government Monday to fulfill its responsibility to the Sickle Cell and Thalassemia community by providing appropriate, comprehensive care for adult patients.
Since 2004, the Coalition has met on several occasions with hospital staff and government officials over the critical lack of space in the Thalassemia and Sickle Cell Clinic at Toronto General Hospital. In spite of repeated pledges to improve access to care and the level of service, one physician said, “The situation has gone from a crisis to a catastrophe.”
About 150 young adults over the age of 18 have no place to go for care. In the last five years, there have been around 15 Toronto area patient deaths, many of which the Coalition said were preventable. Ironically, many of these deaths were patients who had survived blood transfusions in the 1980’s that were contaminated or at risk for HIV and Hepatitis C.
Thalassemia is an inherited blood disorder in which the body is unable to make normal functioning hemoglobin, a protein in the blood required for the transportation of oxygen. Without regular blood transfusions, persons affected are unable to survive. A generation ago, patients rarely lived beyond childhood. Thanks to medical advances, they’re living healthy lives today, pursuing careers, continuing their education and raising families.
For years, Thalassemia patients in Canada had access to the highest standard of care in the world. Unfortunately, provincial funding for the only adult program in Toronto has been capped at 99 patients since the late 1990’s. Once pediatric patients turn 18, they have no place to go for treatment, can’t get the appropriate monitoring for adult care or the right support for emergency cases.
When adult patients develop complications, they are admitted to emergency departments at adult hospitals where their records and hospital files are not available. Physicians are often unaware of problems associated with Thalassemia, so complications develop into more serious conditions.
more...
http://rabble.ca/blogs/bloggers/johnbon/2009/05/sickle-cell-and-thalassemia-patients-can%E2%80%99t-get-proper-treatment-ontar
HemaQuest Initiates Clinical Trials in Sickle Cell Disease and Beta Thalassemia
Venture-backed Firm Seeks Safe and Effective Therapy for Common Life-threatening Genetic Disorders of Hemoglobin05.27.2009 – SEATTLE - HemaQuest Pharmaceuticals announced today that it has initiated clinical trials of HQK-1001 in the treatment of patients with sickle cell disease and beta thalassemia. These two clinical trials are intended to evaluate safety and provide proof of concept clinical data in patients with these serious and life-threatening chronic illnesses.
"Our team is excited to have the opportunity to work with some of the leading clinical investigators to test HQK-1001 in sickle cell disease and beta thalassemia,” said Ron Berenson, M.D., President and Chief Executive Officer of HemaQuest. “There is a pressing need for new drugs to treat these disorders, which cause significant morbidity and early mortality. The goal of our clinical trials is to have sufficient data to move HQK-1001 into advanced clinical studies.”
Each of these blinded, placebo-controlled studies will assess the safety of HQK-1001 and evaluate indicators of therapeutic activity, including several measures of fetal globin, one of the drug’s primary targets. Increases in fetal globin correlate with improved clinical outcomes in patients with these hemoglobin disorders. The trial in sickle cell disease is being conducted at approximately 10 centers in the U.S. The trial in beta thalassemia is being conducted in Thailand, where there is a high incidence of this disease.
more...
http://www.pitchengine.com/hemaquest/hemaquest-initiates-clinical-trials-in-sickle-cell-disease-and-beta-thalassemia/12953/
Classic case of "right thinking" ... thanks for printing this... ~ S
Irvine’s Masimo Rainbow SET may help assess sickle cell
A NIH study indicates the company’s pulse oximetry product provides detailed oxygenation levels.
By Susan Belknapp
Published: May 20, 2009 02:05 AM
Irvine-based Masimo Corp. announced Tuesday that a new National Institutes of Health (NIH) study shows that its Rainbow SET product may help clinicians assess oxygenation in children suffering with sickle cell disease.
The independent clinical study was presented by the American Thoracic Society in San Diego, indicating that the noninvasive measurement of carboxyhemoglobin (SpCO) and methemoglobin (SpMet) with Masimo Rainbow SET Pulse CO-Oximetry is accurate and may help detect hypoexemia – a potentially life-threatening lack of oxygen in the blood of children with sickle cell disease.
Sickle cell disease is an inherited blood disorder characterized by abnormally shaped red blood cells, which compromise vital blood and oxygen supply to the tissue and organs, causing life-threatening complications.
The presence of carboxyhemoglobin and methemoglobin in a sickle cell patient's blood reduces oxygen supply further because these dyshemoglobins that take the place of normal oxyhemoglobin lack the ability to carry oxygen.
However, conventional two-wavelength pulse oximeters are incapable of measuring carboxyhemoglobin and methemoglobin levels, thus they cannot provide clinicians with an accurate picture of true oxygenation status in the presence of dyshemoglobins.
Masimo Rainbow SET-the first-and-only technology that continuously and noninvasively measures SpCO and SpMet, in addition to total hemoglobin (SpHb), oxygen content (SpOC), PVI, oxyhemoglobin (SpO2), pulse rate and PI.
This allows for faster and more accurate assessment of the patient's true oxygenation, which may help to advance the care and management of patients with sickle cell disease.
"This research not only reinforces the clinical accuracy of SpCO and SpMet in assessing the true oxygenation of patients, but also highlights the importance of measuring these dyshemoglobins while managing and treating pediatric patients with sickle cell disease," says Dr. Michael O’Reilly, executive vice president of Medical Affairs for Masimo.
http://www.ocmetro.com/t-Masimo_Rainbow_SET_helps_assess_sickle_cell_5_20_09.aspx
Health Research & Development in Africa
Jennifer Orwa, PhD
Kenya Medical Research Institute,
Center for Traditional Medicine & Drug Research
African Civil Society meeting on the
Intergovernmental Working Group (IGWG) on
Intellectual property, Innovation and Health
28 - 29 August 2007, Nairobi, Kenya
Ok, so it is from 2007, but considerable recognition of our Xechem here... anyway, an interesting read imo
Nigeria: Research by the team at NIPRD,led to the development of herbal medicinal product called Niprisan® for the management of sickle cell anaemiaIn vitro anti-sicklingeffects Collaboration With children hospital of Philadelphia Double-blind, placebo-controlled, randomized cross-over clinical trial at NIPRD clinic, Abuja between 1997 and 1998Nigeria: Research by the team at NIPRD,led to the development of herbal medicinal product called Niprisan® for the management of sickle cell anaemiaIn vitro anti-sicklingeffects Collaboration With children hospital of Philadelphia Double-blind, placebo-controlled, randomized cross-over clinical trial at NIPRD clinic, Abuja between 1997 and 1998
PATENTNIPRISAN was patented in Nigeria, USA, England, and 42 other countries between 1998 and 2000 through a grant by UNDPLICENSING OF NIPRISAN TO XECHEMIn 2002, the Federal Ministry of Health granted XECHEM Inc. an exclusive license for the manufacture, global sale and marketing of NIPRISANMANUFACTURE OF NIPRISANMANUFACTURE NIPRISANXECHEM Pharmaceuticals Nig Ltd has commenced the commercial manufacture of NIPRISAN in Abuja for the global market
http://www.haiafrica.org/downloads/orwa_health_rnd.pdf?34010eb6b1fd6f4a4098bdabfc098e68=9e64bded3b54273505ce0c189014394b
Sickle cell chemical treatment kits run out
Monday, 11th May, 2009
[This is Uganda specific]
By Conan Businge
PUBLIC health facilities have run out of chemicals used to test for sickle cell anaemia.
The chairperson of the Sickle Cell Association, Ruth Nankanja, said the kits ran out last year.
Addressing journalists in Kampala yesterday, Nankanja said a Ugandan US-based captain, Lukiah Mulumba, had donated land at Namalere near Kawanda where a new sickle cell centre would be set up. The centre will be the first of its kind in East Africa.
Currently, Mulago Hospital is the only health facility that has sickle cell units.
There is only one sickle cells specialist in the country. Nankanja said plans were underway to have more doctors trained.
About six million Ugandans suffer from sickle cell anaemia.
Statistics show that about 30,000 babies are born with the disease annually. However, 80% of them die before the age of five.
The health minister, Steven Mallinga, said he was not aware of the shortage. “It might be true, though it had not yet been brought to our attention,” he said.
A sickle cell test in a private laboratory costs over sh20,000.
Sickle cell anaemia is hereditary. People with the disease have red blood cells that contain an abnormal type of haemoglobin.
The disease has no treatment. Patients are offered supportive treatment free of charge at the Mulago clinic.
About 5,000 sickle cell patients are registered with the association.
The clinic receives 200-250 patients daily.
http://www.newvision.co.ug/D/8/13/681006
The declining QC goes back some time already...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=26085685
Wish I could say I was touring promoting Nicosan (Hemoxin) around North America, but I am touring in part for a change of venue and sanity (partly financial pressures) for me, and spend some time with my dad (92).
Left California a month ago, ten days ago I was in Vancouver - and as of yesterday I am in North Bay, Ontario where I will spend the summer. Life is good. Wish I could say that for those who suffer needlessly with SCA. That day will come, but I suspect it has been postponed by another ten years...
Very Nice! ... wonder if that is the same 'list' that Monty purchased? I continue to be amazed by what is available through the Internet, and You continue to have some very valuable contributions. No doubt all of us Xgem enthusiasts appreciate your input.
Perhaps interesting... I happily donated my funds to LaMonty for either Xechem or his personal use - like taking his patient wife (and family) out to dinner and other (many) expenses related to HIS legwork with the X (and thus my funds not going to 'our' lawyer). This was/is money not easily collected, but happily shared. I will continue to maintain the website costs as well (nicosan4all.org) in hope for the time when we can use the site.
Am presently still in BC (with my dad - 92) but departing soon to reach Ontario some time in May... Have a great summer All Xgemers. Keep the Faith.
Only the (very dark) shadow knows (that he is already)...
RS would be a great candidate to work for any major pharmas with clandestine backing!
Have been lurking for months, reading the posts and while not pleased with the results of efforts to date (does not mean i am not pleased with the effort), it is reasuring that there are many who feel the way I do about our BOD and COO (and i have been pleased to support 'change' and correction - although that has now the appearance of being sidelined substantially) ... anyway, what i would really like to learn is who, from what company, convinced RS to bankrupt our Xgem for his personal gain, what that gain consists of, and who else was pulled into this plan. It does appear (at least from my perspective and opinion) very obvious as to what, (as well as how and why) has transpired in the past 20 months. We may never learn the truth of this matter, but surely some/one of us can locate and corner Dr. Swift and have a one on one?
I believe this strategy was/is willful as this company was the subject of RS' vulture approach-purely a corp. finance play from the minute he took over. This is borne out by his fleecing the co. of 5-HMF; the companies only asset aside from Nicosan which now of course has been taken back (temporarily I hope) by NIPRID.
... and the response...
Hello Mrs. Steve,
Thank you so much for your precious information, you have already helped a lott.
I went true the web site and I found, you told me that the only other way we could find excepet true the web site is getting straight from Nigeria, would you have their contact? Maybe we here from Brazil could send or find some how to get for a cheaper price from there, you know why? Is because so mamy people over here have the sickle cell anemia, and most of then do not have treatment, childrens are dieding because do not get medicate, we are trying to help everybody else that have the same problem around here, and we are beliving in Nicosan, but for the price that have been sold in the internet is very hard for to everybody can use, you understand.
So ife you have any other contact straight from Nigeria and be able to send to us it will be very helpfull again. For now thank you so much for all your atencion and help. We really apreciate.
Wating for your answers,
Cheers, Maria.
... obviously this nonsense of lack of production and sales has got to stop and be reversed. We, as a group, did not invest in XeChem to let transpire what has occurred with the present BOD - there is just no excuse imo. Some of us suspect we know the motivation of one or more BOD's. How sad it is.
Aside from this, do we know of another source at this time? Is anything still coming out of XPNL from previous production or has the source now dried up completely to the point that those 'on' Nicosan will not get supplied in the next few months? Are the stockpiles depleted? ~ Steve
I do not believe she has tried to purchase from the exporter, however I will indeed put her in touch with Vixen.
Thanks Dave & Steve
Hi Fellow XeChemaires, received this email this morning and was wondering if anyone now has a source that might work for these folk beyond the googlepages one? http://buy.nicosan.googlepages.com/children)
Thanks.
Hello Mrs. Steve ............
I'm Maria, I'm from Brazil, I have a little friend she is 3 years old and she have the new sickle cell anemia, I have studdy some about the drug Nicosan, and we are very interesting in to try on in the little girl. I having been trying to call few numbers for to know how can we do it for to bay the medicine but is not been sucessfull, finally I fond your contact and I have a big hope that you can help us.
Please we need some help, would you please give us any information how can you do it for to have the Nicosan (Hemoxin).
I'm gonna be waitng for your anwers.
Thank you so much,
Cheers,
Maria Delzedir Ramos da Silva
As for you too CTO, for many here it will not be a challenge...
Have removed the link since it appears it will be quite some time before we are in such a position - where we should have been in years ago...
Appears to be a different Coker ...
Dr. A. J. Coker formerly at SHESTCO
Coker H.A.B. listed in the article ...
Herbal preparation shows promise in tackling sickle cell disorder
Not the same Coker I expect... but what's with new Herbal Preparations being researched and pushed when they already have Nicosan? Does Pandey know some of these folk? Swift?
Thursday, February 19, 2009
http://www.ngrguardiannews.com/natural_health/article01/indexn2_html?pdate=190209&ptitle=Herbal%20preparation%20shows%20promise%20in%20tackling%20sickle%20cell%20disorder
Researchers have tested the efficacy of a herbal preparation in treating sickle cell anaemia. CHUKWUMA MUANYA reports.
RESEARCHERS have enlisted more herbs in the treatment of sickle cell disorder. A herbal product made from local plant-Alchornea laxiflora- has shown promise in a College of Medicine University of Lagos (CMUL), Idi-Araba, study in treating sickle cell anaemia.
Preclinical anti-sickling and haemolytic toxicity studies on the herbal product, Cellod-S, carried out by researchers at Natural Medicine and Molecular Pharmaco-Biotechnology Laboratories Faculty of Pharmacy, CMUL, indicated that the herbal preparation produced 85 per cent sickling inhibition and 69.1 per cent sickling reversal.
The study titled "Does re-hydration necessarily imply re-oxygenation in sickling reversal? The Gardos phenomenon - revisited. A case for cellod-S herbal remedy" was published in Journal of Pharmaceutical Sciences and Pharmacy Practice.
The authors include: Coker H.A.B., Kehinde M.O., Kehinde M.O., Temiye E.O., Banjo A.A.F., Elesha S.O., Sofola O.A., Ajala O.S., Alaribe S.C., Adesegun S.A., Owolabi M.O., Sodipo J.O.A. and Renner J.K..
The researchers concluded: "The results of these pre-clinical evaluations indicate that Cellod-S has the acclaimed antisickling ethnomedicinal use, and thatbhaemolysis - a major mechanism-based toxicity of potential anti-sickling agents, and phenomenon most guided against in sickle cell sufferers- is not a problem with Cellod-S. We therefore recommend Cellod-S for extensive clinical evaluations in humans."
Sickle cell anaemia is a well known inherited disorder of the red blood cells. It affects an estimated 2.5 million Nigerians, killing approximately 60,000 Nigerians every year.
It is estimated that one out of every four Nigerians is a carrier of the sickle cell trait (AS). These groups do not suffer the physiological effects of the sickle cell disorder, but actively transmit it onto their offspring. An estimated 100,000 babies are born each year with the disorder, 80 per cent of who die by the age of five. Majority of the cases are undiagnosed and as a result of infections, the illness is aggravated.
According to Useful Plants of West Tropical Africa by H.M. Burkill, Alchornea laxiflora, which belongs to the plant family Euphorbiaceae is a shrub or forest under-storey tree to six metre high, from Northern and Southern Nigeria and West Cameroons; also widespread in central, eastern and southern tropical Africa.
The leaves are recorded as amongst those used to preserve the moisture of kola nuts in packing. The stems, and especially the branchlets, are used in Nigeria as chew-sticks. The plant enters into a Yoruba incantation to make 'bad medicine' rebound on the sender.
Alchornea laxifora is called uwenuwen in Edo; ububo in Igbo; urievwu in Urhobo; and ij�n, ij�n funfun and ij�nd� in Yoruba.
Until now, decoctions of the leaves are used in the treatment and management of inflammatory and infections diseases as well as an important component of herbal anti-malarial formulations.
Alchornea cordifolia, a closely related species are used in the preparation of remedies for urinary, respiratory and gas to intestinal disorders. Its antibacterial activity on Staphylococcus aureus and Escherichia coli was attributed to Isopentenyl guanidine.
Phytochemical screening of the powdered leaf sample of Alchornea laxiflora revealed the presence of alkaloids, cardiac glycosides, saponins, and phenolic compounds. The presence of terpenoid compound was recently discovered in the root samples of Alchornea laxiflora.
Cellod-S is a powdered plant material product of Supreme Ormed Option Limited Sapele, Delta State, with acclaimed anti-sickling properties. It is registered by the National Agency for Food, Drug Administration and Control (NAFDAC) and is available in capsules for adults and tea form for children. The NAFDAC Registration Numbers are: 04-7663L & 04-7664L. Cellod-S is registered under the Patent and Trade Regulations with the Federal Ministry of Commerce, Abuja, Nigeria.
It has been developed from the initial crude fermented stuff in alcohol and usually taken in glasses several times daily. Cellod-S has been developed to modern production level of capsules and offered on 200mg for adults and granules in tea form for children.
A significant characteristic of Cellod-S is its ability to sustain the patient even when the Packed Cell Volume (PCV) level of the patient is remarkably low.
Phytochemical investigation of the herbal preparation revealed the presence of anthraquinone-O-glycosides and phenolic compounds.
An in-vitro bioassay technique was adopted for the anti-sickling screening- investigating the sickling inhibitory and sickling revrsal activities of one to five mg/ml graded concentrations of Cellod-S extract on sodium metabisulphite- induced sickling in human HbSS erythrocyte (sickle red blood cell) suspension aliquots, the physiological suspending medium (PSM) and 0.25 per cent w/v P-hydroxybenzoic acid (PHBA) serving as negative and positive controls respectively.
Effects of the same extract concentration range on the osmotic fragility of HbSS erythrocytes were investigated by determining Median Corpuscular Fragility (MCF) from the Osmofragiligraphs for HbSS erythrocyte suspensions treated with different extract concentrations within the range. The MCF values were used to draw conclusions on the possible haemolytic tendency of Cellod-S.
Highly statistically significant average per cent sickling inhibitions and average per cent sickling reversals were obtained throughout the one to five mg/ml concentration range. The highest values- 85 per cent sickling inhibition and 69.1 per cent sickling reversal- produced by the five mg/ml extract are higher than the respective 75.4 per cent and 59.3 per cent values obtained for the positive control (PHBA).
Weighed MCFs of 0.400 per cent to 0.411 per cent obtained through the one to five mg/ml extract range were not statistically significantly different from 0.405 obtained for the negative control, that is the suspending medium.
The leader of the team, Coker, said: "The results of these evaluations have scientifically confirmed the acclaimed antisickling properties of Cellod-S, and have shown that haemolytic toxicity- one major mechanism-based toxicity of anti-sickling agents- is not likely to be a problem with Cellod-S. Cellod-S may therefore be considered safe enough for extensive clinical investigations."
Cellod-S, which now comes in 200 milligram capsules was developed by Chief Dr. Mathew O. Origbo. "It achieves sickling reversal and sickling prevention activities. This claim has been verified by the study at the CMUL. Cellod-S sustains a sickle cell patient even when the PCV of the patient is remarkably low and gradually build up the PCV. It eliminates crises, and promotes growth of stunted patients with the growing age. It helps to heal chronic ankle ulcers arising from sickle cell complications. Pregnancy patients are assisted to successfully carry their babies to full term," said Origbo.
He further explained: "It makes the patient well, completely well. But the patient remains a carrier for sickle cell trait. But the patient virtually lives a normal live like other person. So for sickle cell, that is the situation. The sickle cell medicine is almost 100 per cent effective, that is any patient who takes it actually gets well. There have been claims in two instances of cure, one is from a lecturer in Agbor. He actually gave thanksgiving in the church that his daughter changed whether from SS to AS or AA. Then of recent a pharmacist in Benin treating sickle cell twins told my son who introduced it to them that the genotype of the two have changed from SS to AA. This was later last year. Personally for our purpose that is not important because such small minority of people we treat. So, we do not want to make claims to such extension and whether they are actually right we do not know because we did not investigate."
Origbo said Cellod-S is not a palliative but a medicine for treatment of sickle cell. "The patient remains basically a carrier of sickle cell but well. You can see my son unless you are told he is a sickler you would not know. So for sickle cell we can say modesty that we have over 90 per cent success rate, that is the patient becoming well."
He, however, acknowledged that there are no clinical trials on the drug. "In Nigeria there is no formal way to test products. We have written to six universities - University of Benin, University of Lagos, University of Ibadan, University of Nigeria Nsukka, Delta State University Abraka, Obafemi Awolowo University Ile Ife. We put out this medicine down for them that we want trials. Particularly there was a study done on the sickle cell product by the University of Lagos. After this study, one would have expected that the university would have been interested to go further, but No," Origbo said.
He said: "Cellod-S is for the treatment of sickle cell disease. It eliminates symptoms, restores vigour and good health. Cellod-S could be used for other conditions of anaemia and lack of vigour in patients.
"Cellod-S Herbal Tea is administered for children of under ten years old who cannot swallow capsules. A jar of 150 capsules or a herbal tea of 75gm should start off the treatment of sickle cell disease. It should be continued till the patient is free from all the symptoms and full health restored. The duration of treatment depends on the initial health condition of the patient, age and individual response to treatment. For infants, health is more easily restored, while patients who are severely affected may take months and sometimes more than a year of continuous treatment before good health is restored.
"A significant characteristics of the product is it's ability to sustain the patient even when the PCV of the patient is very low. When full health has been restored, the patient should reduce the period of taking the medicine to two weeks in a month, then to a week before finally stopping the medication. If the symptoms manifest again, the patient should resume the treatment.
"It could also be used in the treatment of other ailments: Loss of blood in accident, operation and child birth; Chronic fatigue syndrome; and other forms of blood disorder.
"For these ailments, it is recommended to start the treatment with a jar of 75 capsules. For the case of chronic fatigue syndrome, maintenance dose may be necessary from time to time.
"Patients in crises should start treatment with Cellod-S immediately. Patients in very serious cases should be hospitalized and stabilized but the administration of Cellod-S should continue uninterrupted.
"During the administration of Cellod-S to Sickle Cell patients, high nutritious balanced meals with plenty of fruits and vegetables should be provided to the patient. The intake of balanced meals should be continued even after the patient becomes well
"Cellod-S is not an instant result yielding medicine. Therefore, it does not immediately help to relieve crises or pains in hours. It gradually builds up vigour and good health over time until all the symptoms disappear. No known side effects have been reported.
LaMonte - you have email
Hi Fellow Xechemaires, this time from sunny California. Finally have a decent internet connection (for two months only). I brought my dad (92) here for a respite from the Canadian winter and we are enjoying our time together.
Very pleased with the efforts of several working for the benefit of shareholders here. I am of course concerned about what will be left of the mighty X (and our shares) following the sale of 5-hmf and likely also XPNL, but we all know Nicosan will survive and thrive with or without the X and ultimately that is what is important.
Keep the faith all ~ Steve
Hello Fellow Xechmaires, how are you All? It appears much has changed on the Xgem landscape and for us shareholders since I posted last back in the Summer (from Switzerland). My life also changed dramatically on return to Ontario, Canada, and Xechem has had a hand in that transition, sadly in response to the performance of our COO and directors it appears. I fully believed in management's willingness and ability to do the right thing(s), and in their success at doing these. Like many of us, I suspect our blind faith caught us - being blind. Never have I doubted the viability and success of Nicosan and so I invested heavily, over the top so to speak, as others. The rest is history.
Hard to believe all the support to the company provided by the shareholders, and the hours of research every day performed by many of us over several years have proved fruitless for the betterment of the lives of those suffering. As a result, more suffer - and longer. I wonder if anyone (Dr. Pandey?) ever saw a Business Plan for Xechem. For my part, the changes necessitated by this turn of events finds my 'things' in a storage bin and the 'child', at 56, moving back in with his parents. This sounds worse than it is for the circumstances have afforded me the opportunity to spend some time with my father, who now at 91 has been living alone for the past several years in British Columbia.
Furthermore, to both of our delight, I have talked him into spending three months (God willing) in California where we will rent a trailer in a 'Park'. This will likely be his last 'hurrah' and will be therapeutic, rewarding and enlightening for both of us I expect. As you can imagine, this does not come cheap and so we are spending part of my inheritance (lol) money never spent better. I, like so many of us here, have been impacted by Xechem's BOD performance, a situation that confounds the mind at how such a wonderful product can be suppressed from benefiting the millions it should be by now. Is it ineptitude or planned obsolescence (greed)? Whatever it is, from reading numerous posts here I garner there is much being done to try to ascertain just that. Kudos to all of You for your time and efforts. While I have little or no available time, and ditto for money, I will try to help in some small way. No doubt someone will shed light on how.
May this be a New Year filled with blessings to You and Yours, and for those who might benefit from receiving Nicosan. ~ Steve
"Never doubt that a small group of committed citizens can change the world." - Margaret Mead
PS - for those of you who were in touch by email during the past several years, I gave up my sympatico address last fall but can still be reached on occasion at nicosan4all@gmail.com . I say on occasion because I do not always have Internet access these days.
Hi All, still around like many longs, lots of shares and still reading every post. Have been unable to check every day as I have been touring Switzerland with my father (he is 91 and from here). Though I was born in Montreal, I went to school here in Eggiwil some 44 years ago. The link is where we stayed last night, http://www.berghaus-eggiwil.ch/index-e.html although today we are in Bern (the capital). We borrowed a car from a friend and are driving, visiting the sights, old haunting grounds and playing tourist - with me as chaufeur and dadio paying the bills
Seems our Xgem is hibernating. Something is likely still going on, even with the offices in NJ apparently closed (r we still paying rent?). Am thinking the buildings at Sheda, while technically 'ours', they are on land that does not belong to Xechem ... ( r we still paying rent there also?). Perhaps Dr. Swift has already subleased without our knowledge? To whom? - they still need finishing, but the outfitting could be done by the lessee perhaps.
Is Dr. Pandey still waiting to see if he can somehow rejoin the company? How long is he willing to wait? I am a bit out of the loop for the last month, and am now wondering if we still have some folk (perhaps other than imf) working on something behind the scenes so to speak?
Guess all I have really are questions like most of us. Since we are sort of still trading it appears we will not be delisted for some time yet, possibly having been granted some form of 'extension' for a few months. Seems to me the promise of Nicosan has not died - especially in Nigeria. I have the feeling that the positives with XPNL are greater than with Xintl although obviously the two are tied, and the former is keeping the latter alive - for now at least.
Another feeling I have is that we will get some more news or update in the Fall, perhaps September - and unless there is negative event passage in the meantime we will bump and grind along the .0003 to .0008 range - plenty for some traders to play this every three weeks or so. But like all of us, I really have no clue as to what transpires during the next month - or even today. You pays your money and you takes your chances lol
Hope u r all having an enjoyable summer and will chat at you again later this month when I am back in Canada. ...Till then, keep the Faith §
"The Nicosan train is leaving the station and you had better get on board"
-- Iretiolu Oniyide
"What we see depends mainly on what we look for"
-- John Lubbock
Don't know about the 'wise' part, but here are my thoughts...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=30921771
Yes, a little interesting to see some dumping and some buying... if this action continues tomorrow without a price drop, it could mean news of some kind is coming up imo. 60M shares traded and no real drop shows some serious buying interest, but this action needs to continue tomorrow and Friday with no price drop before I would interpret it as 'good' news. imo again... lmf1264, we hear you...
Nigeria rated the world’s worst country for child survival
Written by Chioma Obinna
Tuesday, 22 July 2008
...As UNICEF launches 2008 Reports
AT first sight, she represented purity and innocence. Moments later, she became restless, her gentle skin became hot. She wailed like a wild animal. Within seconds, she began stooling and vomiting uncontrollably. Her mother held her in a fruitless effort to calm her. The little angel of about 10 months was rushed to a nearby health center where Evelyn, the worried mother, was shocked to discover that there was no health worker in attendance.
Before she could overcome her shock, two other women arrived with their babies strapped to their backs. Unfortunately, before they could be attended to, their innocent babies had passed on. Try as much as Evelyn and the two women could, they could find no answers to the calamity that has befallen them. Why are children still dying as a result of childhood preventable diseases in a country with enough resources? The answer was blowing in the wind for all they cared. This scenario describes the situation in Nigeria and some other African countries.
Each day, 30,000 children aged under-five die. Nearly 99 per cent of these deaths occur in countries like Nigeria and most are preventable. Globally, children die at the rate of 18 per minute.
Regrettably, many in the developing world, and especially the poor, still lack access to basic services, which result in this tragic and needless loss of life. Another sad fact is that most of these developing countries know why children die and what could be done to reduce the incidence but unfortunately, little or nothing is being done to check these deaths.
The fourth Millennium Development Goal (MDGs) aims to reduce by two thirds the mortality rate among children under- five. For Nigeria to achieve this, the country has to reduce its under-five mortality rate to 67 deaths for every 1,000 live births by 2015.
Today, the under -five mortality rates is estimated at 192 per 1,000 live births reflecting the urgent need to accelerate progress in the remaining years to reach the MDGs target.
Understanding the need for a child survival revolution UNICEF is supporting the Nigeria government in implementing the Accelerated Child Survival and development (ACSD) strategy.
Despite this impressive efforts, the 2008 State of the World’s Children Report ranks Nigeria among the 12 countries in the world reporting the highest under- five mortality rates.
At the official presentation this report tagged, “Child Survival” by UNICEF in Abuja last week, UNICEF Representative, Dr. Robert Limlim declared that child survival is central to Africa meeting the millennium development goals.
According to him, child survival is the key to Africa meeting all the millennium development goals because six of the goals have targets that relate directly to children’s health.
Quoting from the state of Africa’s children report, he said Sub- Sahara Africa faces the greatest crisis of child mortality as about 50 per cent of child deaths in the world happen in the region and nearly 50 per cent of children dying in West Africa are in Nigeria.
“Fortunately, most of these lives could be saved by low - cost and high impact interventions like vitamin A supplements and breastfeeding for infants up to six months of age, sleeping under nets treated with insecticide, safe drinking water and basic sanitation and immunization.”
The two reports, State of the World Children’s report and State of African Children’s report with 54 pages also show that more than one million children under -five years of age die annually in Nigeria.
LimLim further noted that nearly a third of the children under five are underweight and half of the population does not have access to improved drinking water sources. He opined that upsurge of children crippled by polio has reached such proportion that urgent and drastic measures have to be taken if Nigeria must interrupt transmission by next year.
He urged Nigerian government to demonstrate increased attention and investment for the survival and development of children.
Tasking Nigeria Government on the children, he said “It must be our top priority for the coming years. It must be a strong bench mark for judging progress of states in the federation, it must become an indicator for leadership accountability and child survival must become a product of dividends of democratic rule.”
Declaring that the report is not so bleak in Africa, he said five African countries, Algeria, Egypt Libya, Morocco and Tunisia reduced their child mortality rates by at least 45 per cent between 1990 and 2006 putting them on track to meet the child survival target.
He further challenged the Nigerian government that if these countries can do it, Nigeria has the potential and resources to achieve greater feats towards the attainment of the MDGs.
Also speaking, the UN Representative, Dr. Alberic Kacou whoo was represented by WHO representative in Nigeria, Dr. Peter Eriki called on government of Nigeria and Africa at large to increase investment in health and nutrition at Federal, state and local government levels so that effective intervention with high impact on child survival can be implemented.
Kacou also called for a renewed effort in polio eradication and the presidential directive to situate the polio eradication in the context of child survival.
He explained that the interventions are part of a comprehensive package to ensure the rights of children to life, survival and development can be achieved in s sustainable way.
http://www.vanguardngr.com/index.php?option=com_content&task=view&id=12785&Itemid=0
Direct Marketing Campaign
Xechem Pharmaceuticals Nigeria a subsidiary of Xechem international Inc started its operation in Nigeria in July 2002 after signing an agreement with the Ministry of Health and NIPRD for research, development, production, worldwide sales and marketing of NICOSAN product developed by NIPRD scientists to manage sickle cell disease.
The company was desirous of a reputable marketing communications firm who will develop effective marketing communications campaign for its indigenous miracle drug to create intense awareness and ensure effective market penetration.
Our Response
Brandmarks conceptualized a direct marketing campaign which covered the following areas:-
Electronic Media
Print Media
BTL Communication Materials
Radio Program Origination (NICOSAN Hour)
Outcome
Campaign was largely successful and the product demand has steadily been on the increase which has positively impacted sales.
http://brandmarkslimited.com/xechem.asp